Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552274 · ClinicalTrials.gov registry record · Early Phase 1
FTIH of ECC4703 in Healthy Volunteers
A Early Phase 1 study, sponsored by Eccogene.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 75
- Enrollment target
NCT05552274 is a Early Phase 1 study that has completed, run by Eccogene. The registered enrollment target is 75 participants.
The verdict
NCT05552274, a Early Phase 1 study, has completed, sponsored by Eccogene.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL
Interventions
- DRUG Placebo
- DRUG ECC4703
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-08-16 |
| Est. Completion | 2023-10-26 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05552274
The ClinicalTrials.gov registry entry for NCT05552274 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eccogene, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05552274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05552274 about?
NCT05552274 is a clinical study titled "FTIH of ECC4703 in Healthy Volunteers". This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL
What is the current status of trial NCT05552274?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 75 participants. The study started on 2022-08-16. Estimated completion is 2023-10-26.
What interventions are being tested in trial NCT05552274?
The interventions under investigation include: Placebo (DRUG), ECC4703 (DRUG).
Who is sponsoring clinical trial NCT05552274?
This trial is sponsored by Eccogene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.